Home >  News >  Industry >  Pharma News >  Gilead Sciences sets...

Gilead Sciences sets aside USD 200 million to resolve HIV drug investigation

By - Ruchika Sharma
Published On 2025-03-04 10:30 GMT   |   Update On 2025-03-04 12:13 GMT
Advertisement

New York: Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into its promotional speakers program for HIV drugs.

The pharmaceutical giant disclosed the potential resolution with the Manhattan U.S. Attorney's office in a securities filing on Friday afternoon

Gilead said it had received a subpoena in 2017, but did not provide additional details about the probe in its filing.

Advertisement
The company, which first disclosed the probe in 2018, said in a statement on Monday: "We have taken a litigation accrual for a potential settlement.
A spokesman for the Manhattan U.S. Attorney's office declined to comment, Reuters said.
Promotional speaker programs in which doctors are paid by drugmakers to deliver lectures about their products have drawn past Justice Department scrutiny.
In 2020, Swiss drugmaker Novartis paid more than $600 million to settle with the Manhattan U.S. Attorney over claims its speaker program was a cover for paying bribes to doctors to prescribe its medication.
Novartis at the time said it was "committed to doing what is right" and had established an enhanced compliance framework.
Gilead's HIV drug sales rose 16per cent to $5.45 billion in the fourth quarter of 2024, contributing to a surge in its share price.
The company expects to launch a new drug, lenacapavir, for protecting against HIV infection later this year.

Read also: Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

B Pharmacy Graduate Held for Operating Unauthorized Clinic in Hyderabad

No Generics for AbbVie's Rinvoq Until 2037, Analysts See Multi-Billion Dollar Boost

Advent to Sell Zentiva to Private Equity GTCR in USD 4.8 Billion Deal, Closing Expected in 2026

Chennai Court Acquits 2 After Alleged Nitravet Haul Found to Be Paracetamol

USFDA warns pharma cos to remove misleading ads

Intas Pharma appoints Dr Ajay Kumar Handa as new Executive Vice President - RnD

Sun Pharma Halol facility gets OAI status from USFDA

Sanofi gets USFDA fast track designation for neovascular age-related macular degeneration gene therapy